Discover open access scientific publications

Search, annotate, share and cite publications

Publications by K. D'Oca

Pcn138 - Cost-Effectiveness Analysis of Pembrolizumab in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Cancer in England

Value in Health

English

Related publications

Pcn139 - Cost-Effectiveness Analysis of Pembrolizumab for Patients With Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Cisplatin-Containing Chemotherapy in England

English

Pcn176 - A Cost-Effectiveness Analysis of Atezolizumab Versus Docetaxel for Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Belgium

English

Cost Effectiveness of Trifluridine/Tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales

Clinical Colorectal Cancer

Oncology

Gastroenterology

2018

English

Pcn178 - Cost-Effectiveness of Pembrolizumab as Second-Line Treatment for Patients With Advanced Urothelial Cancer in France

English

Vinflunine in Platinum-Pretreated Patients With Locally Advanced or Metastatic Urothelial Carcinoma

English

Pembrolizumab in the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Trial Evidence and Experience

Therapeutic Advances in Urology

Urology

2019

English

P3.04-17 Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada

Journal of Thoracic Oncology

English

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy for Previously Untreated Metastatic Non-Small Cell Lung Cancer in the USA

BMJ Open

Medicine

2019

English

KEYNOTE-045: Randomized Phase 3 Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Previously Treated Metastatic Urothelial Cancer.

Journal of Clinical Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by K. D'Oca

Pcn138 - Cost-Effectiveness Analysis of Pembrolizumab in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Cancer in England

Related publications

Pcn139 - Cost-Effectiveness Analysis of Pembrolizumab for Patients With Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Cisplatin-Containing Chemotherapy in England

Pcn176 - A Cost-Effectiveness Analysis of Atezolizumab Versus Docetaxel for Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Belgium

Cost Effectiveness of Trifluridine/Tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales

Pcn178 - Cost-Effectiveness of Pembrolizumab as Second-Line Treatment for Patients With Advanced Urothelial Cancer in France

Vinflunine in Platinum-Pretreated Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Pembrolizumab in the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Trial Evidence and Experience

P3.04-17 Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy for Previously Untreated Metastatic Non-Small Cell Lung Cancer in the USA

KEYNOTE-045: Randomized Phase 3 Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Previously Treated Metastatic Urothelial Cancer.